join piper tirzepatide Beware of Compounded Tirzepatide Weight Loss Injections •

Companies are racing to develop alternatives to injectable diabetes and weight loss drugs Injectable peptide drugs targeting the glucagon-like peptide 1 (GLP-1) receptor have had massive impact on approaches to treating diabetes and obesity, bringing huge revenue boosts to makers Novo Nordisk and Eli Lilly

Clinical trial data from the SAPPHIRE trial demonstrated improvements in motor function and strength, setting it apart from existing SMA treatments that focus on boosting SMN protein

There have been shortages of the drugs

Reducing weight lowers the risk of high blood pressure and cardiovascular disease

The company recently resolved its legal dispute with Hims & Hers Health (HIMS) and is now partnering to offer Ozempic (injections) and Wegovy (both pills and injections), potentially reaching a broader audience in need through expanded distribution